The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

Injectable HIV therapy offers hope for those who struggle with daily pills—providing a powerful, long-lasting alternative to ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

The Kingdom of Eswatini has the highest HIV/AIDS incidence in the world. However, the mission of the Piggs Peak Partnership ...

HIV conference opened in San Francisco Sunday, March 9, under a cloud of uncertainty in the face of the Trump ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

As more heterosexual people are diagnosed with HIV, sexual health stigmas among Māori are putting wahine at risk, a Rotorua ...

It’s a tapu subject,” said Milly Stewart, a specialist indigenous service provider pushing for more public education around ...

The combination of ViiV’s experimental integrase inhibitor cabotegravir and Janssen’s Edurant (rilpivirine), injected every four weeks, could change HIV treatment from 365 dosing days per year ...